View
Page
Northland note out this morning, taken from research tree "SalvaRx announced Final Results for the year ended 31 December 2015. On 22 March 2016, SalvaRx began trading on AIM following completion of the reverse takeover of 3Legs Resources plc and concurrent name change to SalvaRx Group plc. SalvaRx now has exposure to three cancer immunotherapy programmes which are funded through early clinical trials... The market for cancer immunotherapies is forecast to expand to over $80bn by 2020."
Welcome to the new Salvarx Group stream forum! Messages posted in the Salvarx Group stream will be logged here for posterity.
Latest from the Community...
Latest from the Community...
Latest from the Community...